SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 06/12/2006 -- Theravance, Inc. (NASDAQ: THRX) announced today that GlaxoSmithKline (GSK) has enrolled the first patient in a Phase 2b clinical program with compound 642444 ('444), an investigational long-acting beta2 agonist (LABA), in patients with mild to moderate asthma. The collaboration now has two compounds in this phase of development in the Beyond Advair collaboration: '444, a GSK-discovered compound, and 159797 ('797), a Theravance-discovered compound. The goal of this collaboration is to develop a once-a-day inhaled combination medicine comprised of a LABA and a corticosteroid for the treatment of asthma and chronic obstructive pulmonary disease.
